Shares of Moderna dropped 6.62% to $103.77 at 14:47 EST on Thursday, following last session’s downward trend. NASDAQ Composite is falling 0.14% to $12,851.94, following last session’s upward trend, This seems, so far, a somewhat negative trend exchanging session today.

Moderna’s last close was $111.13, 72.02% under its 52-week high of $178.50.

Moderna’s Sales

Moderna’s sales growth is 1841.7% for the current quarter and 19117.5% for the next. The company’s growth estimates for the ongoing quarter is a negative 13.5% and positive 660% for the next.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Volatility

Moderna’s last day, last week, and last month’s average volatility was a negative 2.93%, a negative 2.62%, and a negative 1.58%, respectively.

Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 9.32%, 9.84%, and 10.46%, respectively.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $103.77 at 14:47 EST, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.68.

Moderna’s Moving Average

Moderna’s worth is way below its 50-day moving average of $126.16 and way above its 200-day moving average of $83.45.

Previous days news about Moderna

Moderna to offer vaccine to workers, contractors and board. According to The Wall Street Journal on Tuesday, 29 December, "The Cambridge, Mass., company, which has about 1,200 employees, said the small quantities of vaccine needed for the program are separate from the millions of doses Moderna has committed to the U.S. government."

Moderna in talks with south korea to provide about 40 mln doses of Covid-19 vaccine. According to Business Insider on Wednesday, 30 December, "Moderna Inc. (MRNA) confirmed Tuesday that it is engaged in discussions with the government of South Korea to potentially provide 40 million or more doses of the Moderna COVID-19 Vaccine."

Moderna vaccine shipments to Texas delayed by temperature snag. According to Bloomberg Quint on Wednesday, 30 December, "As of Monday, only 2.13 million people had received shots, even though 11.45 million doses of the vaccines made by Moderna and Pfizer Inc. and BioNTech SE have been distributed.", "At least three shipments of Moderna Inc.’s Covid-19 vaccine arrived in Texas last week with signs that the shots had strayed from their required temperature range, prompting a delay in other deliveries, according to the state hospital association."

LEAVE A REPLY

Please enter your comment!
Please enter your name here